VMC
57
4
DHI
48
4
BBY
46
10
HD
57
2
RIG
60
2
CPB
30
6
DTE
56
2
WM
79
3
APD
59
2
CRM
67
2
BF.B
33
2
NVDA
56
-4
TJX
64
2
GS
75
2
AXP
71
2
MCD
52
2
GOOGL
40
-5
PRGO
39
3
WBA
48
4
RHI
59
2
VMC
57
4
DHI
48
4
BBY
46
10
HD
57
2
RIG
60
2
CPB
30
6
DTE
56
2
WM
79
3
APD
59
2
CRM
67
2
BF.B
33
2
NVDA
56
-4
TJX
64
2
GS
75
2
AXP
71
2
MCD
52
2
GOOGL
40
-5
PRGO
39
3
WBA
48
4
RHI
59
2
Financhill
Back

Lixte Biotechnology Holdings 10K Form

Sell
24

LIXT
Lixte Biotechnology Holdings

Last Price:
1.69
Seasonality Move:
-4.66%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive LIXT News And Ratings

See the #1 stock for the next 7 days that we like better than LIXT

LIXT Financial Statistics

Sales & Book Value

Annual Sales: $200K
Cash Flow: $-957.6K
Price / Cash Flow: 0
Annual Sales: $-0.95
Price / Book: 0

Profitability

EPS (TTM): -1.73000
Net Income (TTM): $-4M
Gross Margin: $0
Return on Equity: 0%
Return on Assets: 0%

Lixte Biotechnology Holdings Earnings Forecast

Key Lixte Biotechnology Holdings Financial Ratios

  • The Selling, General & Administrative Expenses for LIXT have been equal to 377.22% of Gross Profit Margin.
  • The Interest Expense is -0.32% of Operating Income.
  • Per Share Earnings over the last 19 years have been positive in 8 years.

Lixte Biotechnology Holdings Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: LIXT
Website: lixte.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

LIXT Technical Analysis vs Fundamental Analysis

Sell
24
Lixte Biotechnology Holdings (LIXT) is a Sell

Is Lixte Biotechnology Holdings a Buy or a Sell?